Publications

The Chinese investment in Spain

The Chinese investment in Spain

  • 20/03/2018

Spain is every day more attractive to Chinese investors thanks to the industrial know how, the technological innovations and the great deployment of new infrastructure. There are some Chinese investments examples which range from the purchase of the Spanish distributor Miquel Alimentació which had a turnover of 90 billion and 2500 employees, by the Chinese industrial group Bright Food in 2015, to the most recent purchase produced in the last year in which the biggest Chinese investment fund China Orient Hontai Capital acquired the Spanish company Mediapro, owner of the television rights of Spanish football. However, we cannot forget that there are other large-volume investments and of “middle market” made by Chinese investors in Spain.

Spain is the excellent gateway to Europe and Latin America

Spain constitutes the great gateway to the southern Europe and Latin America. Precisely, the Spanish land, sea and air connections and the advanced transportation systems help the Chinese investors to have easy and quick access to both the EU market and the Latin American market. Thanks to all of the advantageous conditions, the Chinese investment has evolved positively over the last years in Spain, and in the Communities such as Cataluña and, especially in the Catalan Capital: Barcelona.

Barcelona is one of the most technological city in the world

In accordance with the ranking of the cities with a higher development level published by Business Insider, Barcelona is the unique Spanish city which, in the 24th place, is included in the list of the most innovative and technological cities from America, Europe and Asia. Actually, the Catalan capital is in the 5th place in the ranking of the most technological European cities and very notable for its biotechnological and pharmaceutical industry.

New focus of Chinese investment

With the purpose of making better the pharmaceutical sector and eliminate the low quality medications, the Chinese Public Administration and the private companies has strengthened its commitment to investigation and technology in order to develop the biotechnological and pharmaceutical industry in China. As a result of this new approach, many Chinese companies are seeking for investment opportunities in the pharmaceutical sector abroad.

JAUSAS in the pharmaceutical sector and Chinese market

At JAUSAS we have the advantage of being the pioneer law firm in Life Science, since our firm originated more than half a century ago to provide legal advice to the pharmaceutical, health and cosmetics industry. Since then, our life sciences lawyers have worked to continue maintaining the innovative and creative vision that is required in serving one of the most regulated sectors of the world.

In the view of the complexity of the Chinese market, Jausas has a specific department, directed by Nieves Briz, partner of the “Corporate and M&A” department, with the Chinses lawyer Wenbo Zhou, with the purpose of providing advice to the Chinese investors in their investments and development of their business in both the pharmaceutical/sanitary sector and other industrial, technological and services sectors.

"JAUSAS worked hard and made a good impression, I think they did their job well," reports one satisfied interviewee.

CHAMBERS & PARTNERS (2018)

Clients describe the team as "very good, quick, responsive and professional."

CHAMBERS & PARTNERS (2018)

The team is praised by clients for its "knowledge of insolvency matters and focus on finding solutions."

CHAMBERS & PARTNERS (2018)

The lawyers are "able to co-ordinate the work with firms abroad to make sure it goes smoothly," and goes on to highlight the firm's "reasonable fees, even in situations with partner involvement."

CHAMBERS & PARTNERS (2018)

"The team's ability to focus on the matters stands out. The lawyers understand the business and combine this with a high level of technical expertise." Another client enthuses: "We really enjoy working with them. The service is excellent."

CHAMBERS & PARTNERS (2018)